Intellia Therapeutics, Inc. (NTLA) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Biotechnology
Intellia Therapeutics, Inc. (NTLA) Profile & Business Summary
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Key Information
| Ticker | NTLA |
|---|---|
| Leadership | John Leonard |
| Exchange | NASDAQ |
| Official Site | https://www.intelliatx.com |
Market Trend Overview for NTLA
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
This model looks at how prices behave over time to describe the current market environment. It focuses on whether price is moving steadily, stalling, or losing momentum, and checks both short-term and weekly trends for confirmation. The goal is not to predict exact prices, but to help understand when conditions are supportive, risky, or unclear.
Current Market Context (Short-Term)
As of 2026-02-06 (ET), NTLA is moving sideways. Price at 12.28 is moving between support near 11.63 and resistance near 13.69. There is no clear direction right now. View Support & Resistance from Options
Why the market looks this way?
Prices have moved back and forth over recent sessions without making steady progress. Trend signals have changed frequently, which suggests the market is stuck in a range. In this environment, chasing moves in either direction is less reliable.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-02-06 (ET)
As of 2026-02-06, NTLA is moving sideways without a clear direction. Over the longer term, the trend remains bullish.
NTLA last closed at 12.28. The price is about 1.3 ATR below its recent average price (13.21), and the market is currently in a sideways market without a clear direction.
The market is moving sideways, with no clear direction. Both upside and downside risks remain in play.
Trend score: 35 out of 100. Overall alignment is unclear. The market is currently in a sideways market without a clear direction. The longer-term trend is still positive, but short-term signals are not yet confirming it.
A key downside level is near 9.74. If price falls below this area, the current upward trend would likely weaken or break.
On 2026-02-05, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
Some late-day positioning was observed, but it lacked strong overnight commitment.
Short Interest & Covering Risk for NTLA
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is above its usual range, suggesting rising pressure on short positions, though not yet extreme. (Historical percentile: 70%)
Structure Analysis
NTLA Short positioning is starting to look crowded. Current days to cover is 7.5 trading days, meaning short positions could unwind at a normal pace. Short covering is likely to have a normal impact on price moves.
Bull Trap Structural Risk
Risk conditions are elevated. Recent price strength may be less stable if selling pressure increases.This indicator is intended as a risk filter, not a directional signal. A High or Extreme reading does not predict an immediate move, but suggests that if prices weaken, downside reactions may be more pronounced.
Elevated short crowding (short interest as a share of float is above normal). In the latest reporting period, short interest continues to increase. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-01-15 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.